aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma received positive feedback from the FDA on the path forward for efzofitimod in pulmonary sarcoidosis. The company plans to submit an IND in June 2026 for a new Phase 3 study, focusing on patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The primary endpoint will be change from baseline in FVC at week 48, and the key secondary endpoint will be change from baseline in the KSQ-Lung score at week 48.
Key figures
- Drug Name
- efzofitimod
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.